Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30096842 | 0.83 | CCR2 (0.35) | SLC6A4SLC6A3SLC6A2CCR2 | |
| SCHEMBL30096856 | 0.82 | KDM1A (0.46) | KDM1ASLC6A4SLC6A3SLC6A2CCR2 | |
| SCHEMBL30096908 | 0.80 | OPRL1 (0.44) | KDM1ASLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL10193786 | 0.76 | KDM1A (0.54) | KDM1ASLC6A4SLC6A3SLC6A2CCR2 | |
| SCHEMBL30096845 | 0.76 | GRIN1 (0.33) | KDM1ASLC6A3SLC6A2OPRL1 | |
| SCHEMBL31504306 | 0.74 | HTR2A (0.41) | SLC6A3SLC6A2OPRL1OPRM1OPRK1 | |
| SCHEMBL5728531 | 0.73 | TACR1 (0.49) | KDM1ASLC6A4SLC6A3SLC6A2CCR2 | |
| SCHEMBL5698913 | 0.70 | KDM1A (0.51) | KDM1ASLC6A4SLC6A3SLC6A2CCR2 | |
| SCHEMBL5698966 | 0.70 | KDM1A (0.51) | KDM1ASLC6A4SLC6A3SLC6A2CCR2 | |
| SCHEMBL28032116 | 0.70 | SLC6A4 (0.54) | KDM1ASLC6A4SLC6A3SLC6A2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156994-A1 | FLUORINE-CONTAINING COMPOUND AND CONTRAST MEDIUM | TDK CORPORATION (JP) | 2024-05-16 | — | — | US | disclosed |
| WO-2022196734-A1 | FLUORINE-CONTAINING COMPOUND AND CONTRAST MEDIUM | TDK株式会社 | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156994-A1 | FLUORINE-CONTAINING COMPOUND AND CONTRAST MEDIUM | AFF1, AFF2, AFF4 | KDM1A 3289/4885SLC6A4 1505/4885SLC6A3 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.